- Home
- XAIR vs ONCO Comparison
XAIR vs ONCO Comparison
Compare XAIR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | ONCO |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.0M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XAIR | ONCO |
|---|---|---|
| Price | $2.16 | $0.54 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $20.00 | N/A |
| AVG Volume (30 Days) | 58.5K | ★ 6.4M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | $815,371.00 |
| Revenue This Year | $4.23 | N/A |
| Revenue Next Year | $108.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $0.09 |
| 52 Week High | $8.19 | $798.00 |
Technical Indicators
Market Signals| Indicator | XAIR | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 37.94 |
| Support Level | $0.44 | $0.09 |
| Resistance Level | $2.66 | $1.02 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 17.02 | 1.39 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.